Skip to main content
Mithra Pharmaceuticals S.A. logo

Mithra Pharmaceuticals S.A. — Investor Relations & Filings

Ticker · MITRA ISIN · BE0974283153 LEI · 5493002FDD273HTEKK14 BR Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-12-19 Major Shareholding Noti…
Country BE Belgium
Listing BR MITRA

About Mithra Pharmaceuticals S.A.

https://www.mithra.com/

Mithra Pharmaceuticals S.A. is a biotech company dedicated to women's health. The company focuses on the development, manufacturing, and commercialization of differentiated drugs and complex therapeutic solutions. Its core areas of expertise include contraception, fertility, and menopause. Mithra aims to transform the women's health sector by providing innovative choices to support and improve the overall quality of life for women.

Recent filings

Filing Released Lang Actions
2023-12-19_Mithra_Press-release_Transparency-notification_GS_FR.pdf
Major Shareholding Notification Classification · 98% confidence The document is a press release from Mithra Pharmaceuticals announcing that it has received 'notifications de transparence' (transparency notifications) from Goldman Sachs Group, Inc. These notifications detail changes in Goldman Sachs' shareholding percentage, specifically crossing or falling below the 3% statutory notification threshold as per Belgian law regarding significant shareholdings. This type of filing, which reports changes in significant ownership levels by external parties (like investment banks or large funds), directly corresponds to the definition of a Major Shareholding Notification (MRQ). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific type of ownership disclosure.
2023-12-19 French
2023-11-23 MITHRA - PV AGEX.pdf
AGM Information Classification · 98% confidence The document text explicitly mentions "ASSEMBLEE GENERALE EXTRAORDINAIRE" (Extraordinary General Meeting) and details the proceedings, including the bureau, composition of the assembly, and the agenda items. The agenda focuses on shareholder resolutions, specifically the renewal of authorized capital and related powers, which are typical subjects for a shareholder meeting. This strongly indicates the document is the official record or minutes of a General Meeting. Since it is an Extraordinary General Meeting (EGM) and deals with corporate governance/shareholder matters, the most appropriate classification among the provided options is AGM-R (AGM Information), as it covers the proceedings and materials of a general meeting, even if it is extraordinary rather than annual. It is not a standard financial report (10-K, IR, ER) or a simple announcement (RPA, RNS).
2023-12-19 French
2023-12-18_Mithra_Press-release_DONESTA-DSMB_EN.pdf
Regulatory Filings Classification · 100% confidence The document is a press release dated December 18, 2023, announcing a positive Data and Safety Monitoring Board (DSMB) opinion regarding the DONESTA® Phase 3 trial for menopause treatment. It discusses clinical trial progress, safety assessments, and plans for regulatory submission (Q4 2024). This type of announcement, focusing on clinical trial milestones and regulatory strategy updates, is characteristic of general investor communications rather than a formal financial report (like 10-K or IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice. Since it is an announcement about ongoing business/clinical development, and it doesn't fit the specific categories like ER (Earnings Release), CAP (Financing), or LTR (Legal Proceedings), it falls best under the general 'Regulatory Filings' (RNS) category as a broad corporate update, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format, RNS is the most appropriate general regulatory/corporate news category for non-standard filings.
2023-12-18 English
2023-12-18_Mithra_Press-release_DONESTA-DSMB_FR.pdf
Regulatory Filings Classification · 100% confidence The document is a press release dated December 18, 2023, announcing positive safety data monitoring board (DSMB) feedback for the DONESTA® Phase 3 program and stating the company's plan to submit for regulatory approval in Q4 2024. This content is a corporate announcement regarding clinical trial progress and future regulatory submissions, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is a general corporate update about product development and regulatory timelines. Since it doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), and it is a formal announcement, it best fits the general 'Regulatory Filings' (RNS) category as a catch-all for significant corporate news that isn't explicitly covered elsewhere, or potentially a general 'Investor Presentation' (IP) if it were a presentation, but it reads like a press release. Given the context of clinical trial updates and regulatory planning, RNS is the most appropriate general classification for this type of announcement when a more specific category like 'LTR' (Legal Proceedings) or 'CAP' (Financing) does not apply.
2023-12-18 French
Attestation (002).pdf
AGM Information Classification · 98% confidence The document is an official attestation ('ATTESTATION') issued by a Notary ('Maître Geoffrey GAUTHY, Notaire') detailing resolutions adopted during an 'assemblée générale extraordinaire' (Extraordinary General Meeting) of the company 'MITHRA PHARMACEUTICALS'. The resolutions concern the renewal of authorized capital, capital increases via debt conversion, and the presentation of related special reports (including a report from the board and a commissioner's report). The presence of detailed voting results and formal legal ratification of shareholder decisions strongly indicates this is a record of a shareholder meeting. This aligns best with the 'AGM Information' category, as Extraordinary General Meetings (EGMs) fall under the general scope of shareholder meetings, which is covered by the AGM-R code, even though the content is highly specific to capital structure changes.
2023-12-08 French
2023-12-04_Mithra_Press-Release_Gedeon Richter China_EN.pdf
Regulatory Filings Classification · 100% confidence The document is a press release announcing a binding Head of Terms agreement between Mithra and Gedeon Richter for the commercialization of two products in China. It details financial terms (milestone payments, royalties) and market context. This type of announcement, which details a significant business transaction (like a licensing deal or partnership) but is not a formal regulatory filing like a 10-K or a specific financial report like an ER or IR, typically falls under general corporate news or transaction announcements. Since there is no specific code for 'M&A Activity' (TAR is for M&A proposals/takeover bids, which this is not, it's a licensing deal) or 'Capital/Financing Update' (CAP, which usually relates to fundraising or debt), the most appropriate general category for a significant corporate announcement that doesn't fit the other specific financial or regulatory reports is the fallback category, Regulatory Filings (RNS), which serves as a catch-all for important, non-standard announcements.
2023-12-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.